1. AB1353 Comorbidity and cost burden of patients prior to use of second line biologic for rheumatoid arthritis. (23rd January 2014) Authors: Trivedi, D.; Rosenblatt, L.; Darkow, T.; Chastek, B.; Hebden, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Differences in survival for patients with metastatic colorectal cancer by lines of treatment received and stage at original diagnosis. Issue 2 (10th October 2014) Authors: Seal, B.; Chastek, B.; Kulakodlu, M.; Valluri, S. Journal: International journal of clinical practice Issue: Volume 69:Issue 2(2015) Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0550 Real-World Treatment Patterns among Rheumatoid Arthritis Patients Who Switch from A Tumor Necrosis Factor Inhibitor To Another Medication. (15th July 2016) Authors: Chastek, B.; Curtis, J.R.; Becker, L.K.; Mahajan, P.; Chen, C. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0177 Real-world interruptions in janus kinase inhibitor therapy observed among biologic-naÏve and biologic-experienced rheumatoid arthritis patients. (12th June 2018) Authors: Chastek, B.; Koep, E.; Mallya, U. G.; Cockerham, A.; Choi, J.; Boklage, S.; Furst, D. E. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗